Brian Stouch

2.2k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Brian Stouch is a scholar working on Molecular Biology, Oncology and Orthopedics and Sports Medicine. According to data from OpenAlex, Brian Stouch has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Orthopedics and Sports Medicine. Recurrent topics in Brian Stouch's work include Bone Metabolism and Diseases (5 papers), Bone health and treatments (4 papers) and Bone health and osteoporosis research (4 papers). Brian Stouch is often cited by papers focused on Bone Metabolism and Diseases (5 papers), Bone health and treatments (4 papers) and Bone health and osteoporosis research (4 papers). Brian Stouch collaborates with scholars based in United States, Belgium and Canada. Brian Stouch's co-authors include Graham Jang, Desmond Padhi, Edward L. Posvar, Liang Fang, Paul J. Kostenuik, Marina Stolina, Michael S. Ominsky, Kelly Warmington, Alan Kivitz and Mark Allison and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Bone and Mineral Research and Annals of the Rheumatic Diseases.

In The Last Decade

Brian Stouch

11 papers receiving 1.2k citations

Hit Papers

Single-dose, placebo-controlled, randomized study of AMG ... 2010 2026 2015 2020 2010 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Stouch United States 7 850 654 649 127 106 11 1.2k
Susan Y. Smith United States 19 828 1.0× 814 1.2× 738 1.1× 153 1.2× 45 0.4× 37 1.4k
Naohiko Hayakawa Japan 12 221 0.3× 83 0.1× 153 0.2× 42 0.3× 22 0.2× 20 594
Katie Stone United States 10 128 0.2× 218 0.3× 393 0.6× 46 0.4× 9 0.1× 20 640
Tianbo Jin China 14 163 0.2× 137 0.2× 99 0.2× 52 0.4× 39 0.4× 35 474
Donald McCarthy United Kingdom 12 296 0.3× 40 0.1× 176 0.3× 81 0.6× 33 0.3× 27 825
Ying‐Chou Chen Taiwan 15 147 0.2× 131 0.2× 173 0.3× 18 0.1× 37 0.3× 57 866
M Andolina Italy 16 215 0.3× 42 0.1× 158 0.2× 76 0.6× 22 0.2× 47 738
A Ryckewaert France 16 138 0.2× 107 0.2× 118 0.2× 53 0.4× 94 0.9× 119 835
Domenico Borzomati Italy 17 141 0.2× 69 0.1× 482 0.7× 13 0.1× 42 0.4× 34 728
Priyanka Singh India 15 185 0.2× 53 0.1× 189 0.3× 163 1.3× 24 0.2× 42 687

Countries citing papers authored by Brian Stouch

Since Specialization
Citations

This map shows the geographic impact of Brian Stouch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Stouch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Stouch more than expected).

Fields of papers citing papers by Brian Stouch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Stouch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Stouch. The network helps show where Brian Stouch may publish in the future.

Co-authorship network of co-authors of Brian Stouch

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Stouch. A scholar is included among the top collaborators of Brian Stouch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Stouch. Brian Stouch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Padhi, Desmond, Mark Allison, Alan Kivitz, et al.. (2013). Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. The Journal of Clinical Pharmacology. 54(2). 168–178. 139 indexed citations
3.
Allison, Mark, et al.. (2012). OP0044 The effects of multiple doses of sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass. Annals of the Rheumatic Diseases. 71. 67–68. 2 indexed citations
5.
Dong, Jennifer, David H. Salinger, Christopher J. Endres, et al.. (2011). Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies. Clinical Pharmacokinetics. 50(2). 131–142. 119 indexed citations
6.
Ominsky, Michael S., Brian Stouch, Joseph A. Schroeder, et al.. (2011). Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 49(2). 162–173. 72 indexed citations
7.
Padhi, Desmond, Graham Jang, Brian Stouch, Liang Fang, & Edward L. Posvar. (2010). Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research. 26(1). 19–26. 603 indexed citations breakdown →
8.
Li, Xiaodong, Kelly Warmington, Qing‐Tian Niu, et al.. (2010). Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. Journal of Bone and Mineral Research. 25(12). 2647–2656. 191 indexed citations
9.
Campbell, Caron, et al.. (2009). Topical clonidine gel reduces pain caused by diabetic neuropathy: Results of a multicenter, placebo-controlled clinical trial. Journal of Pain. 10(4). S55–S55. 7 indexed citations
11.
Capparelli, C., Sean Morony, Kelly Warmington, et al.. (2003). Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats. Journal of Bone and Mineral Research. 18(5). 852–858. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026